2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

By I. Smith, M. Procter, R. Gelber, S. Guillaume, A. Feyereislova, Mitchell Dowsett, A. Goldhirsch, M. Untch, G. Mariani, J. Baselga and 14 more. The Lancet, 2007

1,501 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/897e460e721effd475eac2a9079836a1e5753bda

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

Citations in the corpus

Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer (2014, background): “66 in the pooled United States trials and European Herceptin Adjuvant (HERA) trial.(28,29) These data from large randomized clinical trials establish the principle that systemic therapy advances that lead to improved survival and decreased risk of distant disease also contribute to improved local co”
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. (2008, background): “The humanized HER2 antibody, trastuzumab (Herceptin), was approved by the Food and Drug Administration in 1998 for use in metastatic breast cancer and has subsequently shown clinical benefit when used, in combination with cytotoxic chemotherapy, as first-line or adjuvant therapy (5, 6). Importantly,”
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. (2011, background): “At 2 years of follow-up, there was a significant DFS and OS benefit in patients receiving 1 year of trastuzumab compared with observation only.(16) At 3.”
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. (2013, background): “Since 2005, several of the first-generation adjuvant trials have been updated and have confirmed the disease-free and overall survival benefit offered by 1 year of trastuzumab administered with or after adjuvant chemotherapy.(29-31) Prospective randomized trials, first reported in abstract form in l”
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. (2010, background): “Trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), significantly improves survival in patients with HER2-positive breast cancer in both the metastatic(1-3) and adjuvant settings.(4-9) However, despite this notable success, there is still a need to improve H”
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. (2009, background): “For early-stage, HER2positive breast cancer patients, trastuzumab therapy after chemotherapy offers significant benefit (Smith et al., 2007).”